Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab

Novel monoclonal antibody (mAb)-based therapies targeting CD19 and CD22 (blinatumomab and inotuzumab) have shown high rates of complete remission (CR) and been used as a bridging treatment to potentially curative allogeneic hematopoietic stem cell transplantation (alloHSCT) in adults with relapsed o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wudhikarn, Kitsada, King, Amber C., Geyer, Mark B., Roshal, Mikhail, Bernal, Yvette, Gyurkocza, Boglarka, Perales, Miguel-Angel, Park, Jae H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905691/
https://www.ncbi.nlm.nih.gov/pubmed/35042232
http://dx.doi.org/10.1182/bloodadvances.2021005978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905691/
https://www.ncbi.nlm.nih.gov/pubmed/35042232
http://dx.doi.org/10.1182/bloodadvances.2021005978

Ejemplares similares